07.08.16
Pierre Fabre Pharmaceuticals has entered a research project in translational medicine on a drug target in oncology with David L. Rimm, MD, Ph.D., Professor of Pathology at Yale School of Medicine and the Pierre Fabre’s R&D Translational Medicine department headed by Dr. Alexandre Passioukov.
The collaboration focuses on a precision medicine approach to develop a first-in-class antibody-drug conjugate (ADC) identified by the Pierre Fabre R&D team. Both partners will work on the translational aspects to enable the progression of this drug candidate into clinical trials.
"We are delighted to be collaborating with Yale, a world class university and medical center. This international collaboration reinforces our R&D's organization commitment to work with the best teams in our areas of strategic interest and will reinforce our ability to bring new oncology treatment to patients in the most effective manner» declared Laurent Audoly, Head of Research and Development Pierre Fabre Pharmaceuticals.
The collaboration focuses on a precision medicine approach to develop a first-in-class antibody-drug conjugate (ADC) identified by the Pierre Fabre R&D team. Both partners will work on the translational aspects to enable the progression of this drug candidate into clinical trials.
"We are delighted to be collaborating with Yale, a world class university and medical center. This international collaboration reinforces our R&D's organization commitment to work with the best teams in our areas of strategic interest and will reinforce our ability to bring new oncology treatment to patients in the most effective manner» declared Laurent Audoly, Head of Research and Development Pierre Fabre Pharmaceuticals.
